TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9097275
Drug: Interferon-alpha treatment
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha treatment for both groups
Study: 22302034
Drug: γ-secretase modulator
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: γ-secretase modulator E2012
Study: 8899080
Drug: Butyrate enemas
Normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butyrate enemas (60 mL of 80 mM sodium butyrate)
Study: 8153771
Drug: Cefotaxime 500
Normalized name: cefotaxime 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 500 mg
Study: 18313556
Drug: Sequential designs
Normalized name: Designer Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential designs (group sequential designs, boundaries designs, adaptive designs)
Study: 17201235
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of betamethasone
Study: 1378139
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nifedipine sustained-release (SR)
Study: 6357270
Drug: Weekly cardiotocography
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly cardiotocography (antenatal fetal heart rate monitoring)
Study: 26742388
Drug: Liquid medication
Normalized name: Medicated Liquid Soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid medication
Study: 29154054
Drug: Chamomile extract
Normalized name: Chamomile Extract
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile extract capsules (200mg) twice a day for 28 days
Study: 29154054
Drug: Wheat flour
Normalized name: Wheat Flour
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat flour capsules (200mg) twice a day for 28 days (Control)
Study: 21620309
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group attended a 30-minute educational session on safe use of over-the-counter medications.
Study: 11777488
Drug: Contraceptive patch
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive patch (ORTHO EVRA/EVRA) applied 1/week for three cycles (3 weeks/cycle)
Study: 15944559
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection (placebo)
Study: 9107203
Drug: Process consultation
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Process consultation with nurse manager-consultant meetings (high-dose)
Study: 22764197
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 µg daily for 12 weeks)
Study: 21577221
Drug: Arbaclofen placarbil
Normalized name: Arbaclofen Placarbil
DrugBank: Arbaclofen Placarbil (DB08892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arbaclofen placarbil (AP) 20 mg
Study: 21577221
Drug: Combined Arbaclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined Arbaclofen placarbil (AP) 20/30 mg
Study: 16814131
Drug: Transdermal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal hormone replacement therapy (HRT) with continuous transdermal estradiol patch (36 microg/day) plus cyclic oral medroxyprogesterone acetate (MPA; 2.5 mg/day for 12 days) for 12 months
Study: 17283312
Drug: Controlled-release carbamazepine
Normalized name: carbamazepine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release carbamazepine (200 mg twice daily)
Study: 22704112
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ubiquinol daily for 26 weeks
Study: 22118754
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g fructose and 33.3 g erythritol
Study: 22118754
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g fructose and 50 g glucose
Study: 22118754
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g fructose alone
Study: 26182832
Drug: CXCR2 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CXCR2 antagonist AZD5069 (100 mg), twice daily orally for 6 days
Study: 26182832
Drug: CXCR2 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CXCR2 antagonist AZD5069 (100 mg)
Study: 24377096
Drug: Multilayered Compression
Normalized name: zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multilayered Compression Therapy (MCT), n = 23
Study: 3301458
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (550 mg initially, 275 mg every 6 h thereafter)
Study: 23301475
Drug: Auricular point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular point sticking with vaccaria seed at Endocrine (CO18), Mammary Gland, etc., pressed 3 times daily for 1-2 min each time
Study: 319006
Drug: Atenolol 3
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 3 mg intravenous
Study: 27220675
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol with 600 mg of Mg sulfate
Study: 23328380
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of GlideScope and fiberoptic bronchoscope (G+F)
Study: 18663331
Drug: Monthly dietetic
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly dietetic consultations for 6 months
Study: 23652751
Drug: Etoricoxib treatment
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib treatment
Study: 9433650
Drug: Single and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and repeat doses of grepafloxacin
Study: 15002680
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to substance abuse treatment
Study: 15002680
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to substance abuse and mental health treatment
Study: 19447479
Drug: 12 monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 12 monthly cycles of paclitaxel (175 mg/m2 over 3 h)
Study: 19447479
Drug: 3 monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 monthly cycles of paclitaxel (175 mg/m2 over 3 h)
Study: 4020569
Drug: Traditional oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional oral fluid replacement (sodium 35 mmol/L)
Study: 15018852
Drug: Famciclovir 750
Normalized name: famciclovir 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 750 mg once daily
Study: 21784047
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (400 mg iron daily for 4 months)
Study: 31475798
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus aspirin
Study: 10099053
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ebastine (elderly)
Study: 28544600
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (30 mg/kg in 5 min)
Study: 20456486
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg acetylsalicylic acid daily for 7 days
Study: 3392421
Drug: Killed whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed whole cell (WC) oral cholera vaccine
Study: 20861135
Drug: G-CSF 5
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF 5 μg/kg b.i.d. subcutaneously for 5 days
Study: 7502115
Drug: MiniMed implantable
Normalized name: homatropine hydrobromide Ophthalmic Solution [Minims Homatropine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MiniMed implantable insulin pump (MIP)
Study: 18315451
Drug: Acetyl-L-carnitine (ALC)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALC) 500 to 1500 mg b.i.d.
Study: 31472087
Drug: Alveolar ridge
Normalized name: BLUE RIDGE BLUEBERRY
DrugBank: Blueberry (DB10629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alveolar ridge preservation with adjunctive use of enamel matrix derivative (EMD)
Study: 7937278
Drug: Isoniazid tablets
Normalized name: Isoniazid Tablets
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid tablets 300 mg
Study: 21842241
Drug: Combination PPI
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination PPI plus rebamipide
Study: 19277410
Drug: Manual dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual dosage by experienced medical staff
Study: 9853542
Drug: Beta-carotene (betaC)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (betaC) supplementation (30 mg daily)
Study: 30573480
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with an ACE inhibitor (perindopril) and a beta-blocker (bisoprolol)
Study: 21063906
Drug: Corn gluten
Normalized name: AMINO ACIDS, CORN GLUTEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn gluten meal (CGM) at 100 g kg⁻¹
Study: 26355170
Drug: Augmented group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented group with longer implants (at least 11.5 mm)
Study: 1490666
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with rhGH (2.6 IU/m2 daily) and oxandrolone (0.1 mg/kg body weight orally)
Study: 16750207
Drug: Estradiol treatment
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol treatment
Study: 2852792
Drug: Rhesus rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus rotavirus vaccine (MMU-18006)
Study: 20736449
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg daily for 14 days
Study: 29923478
Drug: Weekly 8-session
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly 8-session worry intervention group (n = 7)
Study: 2609991
Drug: Pindolol 5
Normalized name: pindolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 5 mg thrice daily
Study: 24445356
Drug: Injection therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection therapy
Study: 20441717
Drug: Olanzapine ODT
Normalized name: Olanzapine Orally Disintegrating Tablets
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine ODT (10 mg od, 8 days)
Study: 15828904
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium carbonate alone
Study: 15828904
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium carbonate plus vitamin D sterol
Study: 21226886
Drug: Control (independent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (independent of drug use)
Study: 17006875
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg immediately following surgery and every 24 h for a further three days
Study: 11268298
Drug: Hormone-based therapies
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone-based therapies (progestins, androgens, GnRH analogs)
Study: 8501340
Drug: Clofazimine 50
Normalized name: clofazimine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofazimine 50 mg daily
Study: 25170226
Drug: 250 mg/d
Normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/d PI-88
Study: 25985038
Drug: Epinephrine solution
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine solution (control)
Study: 27175680
Drug: Fentanyl 20
Normalized name: fentaNYL 200 mcg buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 20 μg/kg diluted to 100 mL in 0.9% saline
Study: 27118812
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein (CRP) >10 mg/L
Study: 11434597
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon alpha (IFN-α) with ribavirin (approximately 14 mg/kg/day for 3 months)
Study: 9197945
Drug: RP 60180
Normalized name: RP-72
DrugBank: RP-72 (DB17156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RP 60180 (1.0 mg)
Study: 21368592
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor
Study: 24020899
Drug: pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone 45 mg daily
Study: 21949991
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg ginaton by vein, once a day for 14 days (Group A)
Study: 21601481
Drug: Target Hb
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Target Hb value in subnormal range (110‐129 g/l), group 1, n=43
Study: 28818518
Drug: Seladelpar 50
Normalized name: Seladelpar
DrugBank: Seladelpar (DB12390)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seladelpar 50 mg/day
Study: 28818518
Drug: Seladelpar 200
Normalized name: Seladelpar
DrugBank: Seladelpar (DB12390)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seladelpar 200 mg/day
Study: 20638563
Drug: Diclofenac slow
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac slow release 75 mg twice a day plus omeprazole 20 mg once a day
Study: 23530709
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg once daily
Study: 7926494
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily
Study: 8222667
Drug: Antihypertensive drug
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drug treatment
Study: 23591549
Drug: Bilateral ultrasound-guided
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ultrasound-guided subcostal TAP block injections after induction of general anesthesia
Study: 3520389
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion with micropump CPI 9100 Lilly
Study: 29481979
Drug: 18 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 sessions of spinal manipulative therapy (SMT)
Study: 23183149
Drug: Oral fluid
Normalized name: cascara sagrada ORAL FLUID EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluid rapid HIV testing
Study: 9868662
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g plus gentamicin 3 mg/kg once daily for 2 weeks
Study: 15370581
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment, daily subcutaneous injections for 4 weeks
Study: 16797329
Drug: Alendronate treatment
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate treatment
Study: 26366481
Drug: Levothyroxine (LT4)
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (LT4) treatment
Study: 7751690
Drug: Alternating zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alternating zidovudine and didanosine therapy
Study: 21844495
Drug: Carboplatin plus
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin plus paclitaxel 175 mg/m²
Study: 11874940
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pioglitazone
Study: 8411145
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (2.4 g long‐chain n‐3 fatty acids/day) for 4 weeks
Study: 18279551
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (20 mg/d)
Study: 25894865
Drug: Selenomethionine (SeMet)
Normalized name: selenomethionine
DrugBank: Selenomethionine (DB11142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selenomethionine (SeMet) 200 μg daily (n = 28)
Study: 19646212
Drug: MSP3-LSP candidate
Normalized name: LSP-GR3
DrugBank: LSP-GR3 (DB16934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSP3-LSP candidate vaccine
Study: 19646212
Drug: Tetanus toxoid
Normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus toxoid vaccine (Control)
Study: 8787251
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion during CPB
Study: 25169846
Drug: Clarithromycin plus
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin plus neuraminidase inhibitors
Study: 16037127
Drug: Water drink
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL SOLUTION [MAGIC WATER DRINKS, LLC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water drink (7.5 ml/kg body wt)
Study: 1630666
Drug: Bezafibrate 400
Normalized name: bezafibrate 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate 400 mg daily
Study: 10509550
Drug: Felodipine-metoprolol combination
Normalized name: felodipine / metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine-metoprolol combination tablet (Logimax)
Study: 25370206
Drug: 20-mg tadalafil
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg tadalafil
Study: 20156156
Drug: Second- and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second- and third-line antituberculosis agents
Study: 16180526
Drug: Psychodynamic short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychodynamic short-term psychotherapy (PSTP), 25 therapy sessions
Study: 24576886
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy only (Control group)
Study: 2233904
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving the same vaccine at the age of 24 months
Study: 23718078
Drug: Combined application
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined application of gas-air carbonate baths and lysozyme inhalation
Study: 7667826
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg protamine/100 U UFH
Study: 7667826
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg protamine/100 anti‐Xa U LMWH
Study: 21351838
Drug: Controlled-release vaginal
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release vaginal dinoprostone pessary
Study: 12813199
Drug: Diuretic renogram
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic renogram with furosemide after vigorous intravenous hydration
Study: 9264050
Drug: Estazolam drops
Normalized name: Estazolam
DrugBank: Estazolam (DB01215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estazolam drops (test formulation)
Study: 6969194
Drug: tiaprofenic acid
Normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiaprofenic acid 200 mg t.d.s.
Study: 6793053
Drug: Halothane or
Normalized name: Halothane
DrugBank: Halothane (DB01159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Halothane or morphine plus nitrous oxide
Study: 18202320
Drug: FIR therapy
Normalized name: Douglas fir pollen extract
DrugBank: Pseudotsuga menziesii pollen (DB10986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIR therapy in patients undergoing hemodialysis
Study: 11874940
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg pioglitazone
Study: 28591082
Drug: SoluMatrix indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SoluMatrix indomethacin 40 mg twice daily
Study: 30155761
Drug: Betalain-rich beetroot
Normalized name: Maltose-rich malted barley extract
DrugBank: Barley malt syrup (DB14601)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betalain-rich beetroot concentrate (BLN) 100 mg/day
Study: 25493942
Drug: MNP -
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MNP - Fe (5 mg zinc)